Immunotherapy in Older Adults with Cancer

被引:0
作者
Richard Curtis Godby
Douglas B. Johnson
Grant R. Williams
机构
[1] University of Alabama at Birmingham,Internal Medicine
[2] Vanderbilt University Medical Center,Division of Hematology/Oncology
[3] University of Alabama at Birmingham,Division of Hematology/Oncology, Geriatrics, and Palliative Care, Institute of Cancer Outcomes and Survivorship, O’Neal Comprehensive Cancer Center at UAB
来源
Current Oncology Reports | 2019年 / 21卷
关键词
Immunotherapy; Geriatric oncology; Aged; Immunosenescence; Immune checkpoint inhibitors; Clinical trial representation;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 355 条
[1]  
Smith BD(2009)Future of cancer incidence in the United States: burdens upon an aging, changing nation J Clin Oncol Off J Am Soc Clin Oncol 27 2758-2765
[2]  
Smith GL(2012)Under-representation of older adults in cancer registration trials: known problem, little progress J Clin Oncol Off J Am Soc Clin Oncol 30 2036-2038
[3]  
Hurria A(2015)Geriatric assessment-identified deficits in older cancer patients with normal performance status Oncologist 20 379-385
[4]  
Hortobagyi GN(1997)Cancer chemotherapy in older adults. A tolerability perspective Drugs Aging 10 34-49
[5]  
Buchholz TA(2000)General guidelines for the management of older patients with cancer Oncology (Williston Park) 14 221-227
[6]  
Scher KS(2018)Chemotherapy toxicity risk score for treatment decisions in older adults with advanced solid tumors Oncologist 23 573-579
[7]  
Hurria A(2011)Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study J Clin Oncol Off J Am Soc Clin Oncol 29 3457-3465
[8]  
Jolly TA(2018)Geriatric assessment: precision medicine for older adults with cancer Journal of oncology practice / American Society of Clinical Oncology 14 97-98
[9]  
Deal AM(2016)The development of immunotherapy in older adults: new treatments, new toxicities? Journal of geriatric oncology 7 325-333
[10]  
Nyrop KA(2003)Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty Immunol Cell Biol 81 487-495